your market intelligence analyst
Search Results
Edit Save
125 results
Ovarian Cancer News Today 10/18/2019 09:04
The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous lines of treatment.
Ovarian Cancer News Today 10/09/2019 11:49
The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track designation is given to investigational compounds that show considerable potential in treating serious conditions for which available treatments still fall short. This designation is meant […]. .
Ovarian Cancer News Today 10/07/2019 13:32
ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to exploratory analysis on the data of the FORWARD I Phase 3 trial (NCT02631876).
Ovarian Cancer News Today 10/02/2019 10:15
Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2 clinical trial.
Ovarian Cancer News Today 09/30/2019 11:12
Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer, a new study suggests. The study, “Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study,” was published in the journal Gynecologic Oncology. Non-epithelial […]. .
Ovarian Cancer News Today 09/27/2019 12:36
Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients’ response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the European Society for Medical Oncology (ESMO) Congress 2019, […]. .
Ovarian Cancer News Today 09/25/2019 10:32
Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). The agreement gives Spherix rights to a patent application, now under consideration by the U.S. Patents Trademark Office. Spherix has until early December to execute […]. .
Ovarian Cancer News Today 09/23/2019 12:46
On Sept. 20, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and the European Society of Gynaecological Oncology (ESGO) presented the first World Gynecologic Oncology Day (World GO Day). Spearheaded by ENGAGe, the initiative, set to occur annually, aims to promote collaboration among patient groups, strengthen local advocacy activities, and provide an engagement platform. […]. .
Ovarian Cancer News Today 09/20/2019 11:32
For the first time, scientists have found evidence that pain is an independent marker for overall survival in recurrent ovarian cancer, with women with pain living for significantly less time after their diagnosis than those without pain. The survival toll is particularly high for patients with pain despite receiving pain medication, who have seven months […]. .
Ovarian Cancer News Today 09/18/2019 11:12
IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene. Such mutations are linked to some types of ovarian and other cancers. Under the partnership, IMV will use its proprietary DPX drug delivery platform to design an immunotherapy using small molecules provided by […]. .
Ovarian Cancer News Today 09/16/2019 12:26
The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care have entered a collaboration with Personalis to use its cancer immunogenomics platform to identify which ovarian cancer patients respond to a new combination therapy — Lynparza (olaparib) plus the investigational immunotherapy tremelimumab.
Ovarian Cancer News Today 09/11/2019 10:01
Efforts including financial assistance, fundraising and education are underway to mark Ovarian Cancer Awareness Month. The annual September observance includes specialty lender Fifth Season Financial, which seeks to ease the financial burden of treatment of ovarian cancer, prostate cancer and other advanced-stage disorders. The lender’s Funds for Living and Giving (FLAG) program advances a substantial portion of […]. .
Ovarian Cancer News Today 09/09/2019 13:30
A new assay that grows patients’ cancer tissue in the lab and tests for treatment sensitivity may be able to spot ovarian cancer patients likely to respond best to first-line chemotherapy, a study showed. The ex vivo 3D cell culture (EV3D) assay, developed by Kiyatec, may lead to better informed treatment decisions and superior patient […]. .
Ovarian Cancer News Today 09/06/2019 11:43
A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase 1 study. While chemotherapy and immunotherapies have shown promise in fighting ovarian cancers, their activity may be boosted by increasing the number of immune cells […]. .
Ovarian Cancer News Today 09/04/2019 10:22
Researchers have discovered a “don’t eat me” signal that is deployed by ovarian and breast cancer cells to evade a person’s immune system. Similar to other anti-cancer therapies in use or under testing, blocking this signal raises hope for a new class of immunotherapies to combat these cancers. A team at Stanford University’s School of […]. .
Ovarian Cancer News Today 08/28/2019 13:32
The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with a gynecologic oncology expert. The OVATION 2 trial (NCT03393884) is enrolling at 34 sites across the U.S. It will test the safety and effectiveness of GEN-1 […]. .

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications